In the therapeutic field of skin diseases, the G-BA has assessed XX medicinal products in XX individual procedures. Weighted according to the respective patient share in the resolution, a major additional benefit has been shown for xx% of the subpopulations. A considerable additional benefit has been demonstrated for XX% with a minor additional benefit in relation to the comparative treatment for XX%. A non-quantifiable additional benefit has been proved for XX% of the subpopulations. For XX% of the subpopulations as weighted by resolution shares, no additional benefit was proved, corresponding to xx% of the theoretical maximum population of xx million patients.